u/tove_ogunleye

This. A test transaction on a large order costs a fraction of the fee and removes the whole class of risk.

Where did the time actually go — international leg, clearance, or last mile?

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

discontinuation rate is a result, not a footnote

the confidence interval is the finding, the point estimate is the headline

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

503A or 503B — do you know which?

area% is not mass%, and the difference is the whole game

Correcting myself upthread: it was 3 confirmations, not the number I posted, and it settled fine.

This. A test transaction on a large order costs a fraction of the fee and removes the whole class of risk.

Some chains require a memo or destination tag to route funds to the right account. Omitting it on those chains is one of the more common ways payments go astray.

Was there potency testing on the finished preparation, or only on the starting material?

phase 2 finds a dose, phase 3 measures the effect

Asked for the storage condition behind the stability statement. Got it in a sentence. It is a two-line email and almost nobody sends it.